UNIQUE PHARMA QUALITY: Premium pharmaceutical grade Methenolone Enanthate (Primobolan) manufactured under strict GMP conditions with 99.8% purity verification.
Primobolan from Unique Pharma represents our commitment to delivering exceptional quality performance enhancement compounds. Each batch undergoes rigorous testing to ensure consistent potency and purity standards.
Key Characteristics of Primobolan
This injectable compound is administered via intramuscular injection and remains active in your system for approximately 14 Days. Notable features include:
- Pharmaceutical grade manufacturing
- Batch-tested for purity and potency
- Consistent dosing per unit
- Optimal bioavailability
Primary Benefits:
- Enhanced performance and recovery
- Quality-assured formulation
- Reliable and consistent results
- Professional-grade compound
Mechanism of Action
Methenolone Enanthate works by interacting with androgen receptors in muscle tissue, promoting protein synthesis and nitrogen retention. This creates an optimal environment for muscle development and recovery. The compound's unique molecular structure provides specific benefits that distinguish it from other options in its class.
Usage Guidelines
Unique Pharma Primobolan is suitable for experienced users who understand proper cycling protocols. Always consult with a healthcare professional before beginning any supplementation regimen. Proper post-cycle therapy should be considered based on individual needs and cycle duration.
Recommended Applications
This compound is commonly incorporated into both bulking and cutting protocols depending on the user's specific goals. Its versatility makes it a popular choice among athletes and bodybuilders seeking reliable results.
Potential Considerations
As with any performance compound, users should be aware of potential effects and monitor their response accordingly. Regular health monitoring is recommended during use. Individual responses may vary based on genetics, diet, training, and other factors.
Quality Assurance
Every Unique Pharma product undergoes comprehensive quality control including:
- Raw material verification
- In-process testing
- Final product analysis
- Stability testing
Warning: Keep out of reach of children. For adults only. Not intended for use by individuals under 18 years of age.
Related products
Other Unique Pharma products
1. Description (Clinical summary)
Primo 100 mg/mL — containing the active compound methenolone (commonly known by the trade name Primobolan) — is an androgenic–anabolic steroid (AAS). Methenolone is available in injectable (enanthate ester) and oral (acetate salt) formulations. The injectable enanthate is typically a long‑acting intramuscular oil solution. Historically, methenolone has been used therapeutically for conditions associated with catabolism and muscle wasting, chronic illness‑related weight loss, and (less commonly today) certain anemias. Because it has relatively low androgenic activity and low aromatization to estrogen, it has been preferred in some settings when minimizing estrogenic side effects was desirable.
Important regulatory note: methenolone products are controlled in many countries and are prescription medicines. Non‑medical use (for athletic performance or physique enhancement) is associated with health risks and legal consequences.
2. How does primobolan work? (Mechanism of action)
- Methenolone is a synthetic derivative of dihydrotestosterone (DHT). It exerts effects mainly by binding to androgen receptors in target tissues.
- Activation of androgen receptors increases anabolic processes: enhanced protein synthesis, improved nitrogen retention, and stimulation of erythropoiesis (red blood cell production). These actions can support lean tissue maintenance and recovery from catabolic states.
- Methenolone has a high anabolic-to-androgenic ratio compared with testosterone and is chemically modified so that it is only minimally aromatized to estrogen; consequently, estrogen‑mediated side effects (gynecomastia, significant water retention) are less common.
- Despite a lower androgenic profile, methenolone still suppresses the hypothalamic–pituitary–gonadal (HPG) axis, which can reduce endogenous testosterone production and impair spermatogenesis.
- The oral acetate form (alkylated at the 17α position) has higher potential for hepatotoxicity than the injectable enanthate; injectable forms are generally less damaging to the liver but still carry other systemic risks.
3. Dosage (Medical and varying usage guidelines)
All dosing should be determined and supervised by a qualified clinician. The following are generalities drawn from clinical use reports and published experience; they are not prescriptions.
Medical/therapeutic use
- Historically, therapeutic regimens tended to use relatively low, individualized doses tailored to the indication, patient size, and comorbidities.
- Reported clinical dosing (historical) for the injectable enanthate has often been in the low‑dose range (for example, single‑digit to low two‑digit mg quantities per kilogram cumulatively over weeks). In practical clinical terms this translated to relatively infrequent low doses such as on the order of tens to low hundreds of milligrams per dosing interval rather than the high weekly amounts seen in non‑medical use.
- The oral acetate form used historically for wasting or certain anemias was given at modest daily doses, titrated to effect and tolerability.
- Because formal, modern therapeutic guidelines for methenolone are limited, any medical use should follow a specialist’s prescription and be accompanied by appropriate monitoring (see Section 4).
Non‑medical/athletic contexts (reported ranges; not medically recommended)
- Anecdotal and non‑medical reports often use much higher doses than therapeutic practice. In men, reported ranges for injectable methenolone enanthate have been approximately 200–600 mg per week; in women, reported doses are much lower (commonly 25–50 mg/week) due to virilization risk.
- These higher doses substantially increase the risk of adverse cardiovascular, endocrine, psychiatric, and reproductive effects and are not endorsed medically.
Practical considerations
- Frequency and dose depend on formulation (ester length), clinical goal, and patient factors. Injectable enanthate is long‑acting; clinicians may space injections weekly to every few weeks depending on pharmacokinetics and indication.
- Duration of use should be the minimum necessary for the therapeutic goal. Longer durations increase the likelihood of HPG suppression and other adverse events.
- If methenolone is used in a treatment context, baseline and periodic monitoring (see Section 4) are required; concomitant treatments (e.g., testosterone replacement after suppression) should be decided by a specialist.
Contraindications and special populations
- Contraindicated in pregnancy and in women who are breastfeeding.
- Use is generally avoided or very cautiously considered in patients with prostate or breast cancer, severe heart disease, uncontrolled hypertension, significant hepatic dysfunction (especially with oral formulations), or severe renal impairment.
- Pediatric use is generally contraindicated except in very specific and closely supervised circumstances.
4. Side effects (Common and rare adverse effects)
Common/expected effects
- Endocrine: Suppression of the HPG axis — decreased endogenous testosterone production, decreased sperm production, testicular atrophy with prolonged use.
- Dermatologic: Acne, oily skin.
- Hair: Acceleration of androgenetic alopecia in genetically predisposed individuals.
- Psychiatric/behavioural: Mood changes, irritability, aggression, and occasionally depressive symptoms during or after use.
- Injection‑related: Pain, swelling, erythema, or sterile abscess at the injection site.
Metabolic and cardiovascular
- Adverse changes in lipids: reduction in HDL cholesterol and possible increase in LDL cholesterol — atherogenic effects that raise cardiovascular risk over time.
- Hypertension and fluid retention are possible but tend to be less pronounced with methenolone than with aromatizing AAS.
- Increased hematocrit/hemoglobin due to erythropoiesis — raises thrombosis risk if polycythemia occurs.
Hepatic
- Injectable methenolone (enanthate) is less hepatotoxic than 17α‑alkylated oral AAS, but liver function abnormalities can still occur, especially with concurrent hepatotoxic drugs or alcohol. Oral acetate form has higher liver toxicity risk (cholestatic jaundice, elevated transaminases).
Virialization (especially in women)
- Deepening of the voice, clitoral enlargement, menstrual irregularities, increased body/facial hair. Some changes may be irreversible if not stopped promptly.
Rare but serious risks
- Thromboembolic events (deep vein thrombosis, pulmonary embolism).
- Myocardial infarction, cerebrovascular accident — more likely with long‑term abuse or in presence of cardiovascular risk factors.
- Severe hepatic injury (more with oral alkylated forms).
- Severe psychiatric disturbance, including mania or severe depression in predisposed individuals.
- Hypersensitivity or allergic reactions (rare).
Monitoring during therapy (recommended)
- Baseline: CBC (hematocrit/hemoglobin), fasting lipid profile, liver function tests (AST/ALT, bilirubin), serum testosterone, PSA in men, blood pressure, and pregnancy testing in women of childbearing potential.
- Ongoing: periodic monitoring of the above (intervals depend on dose/duration; for chronic therapy commonly every 1–3 months initially, then spaced if stable). Monitor for virilization in women and signs of HPG suppression in men.
- If significant adverse changes occur (marked lipid derangement, polycythemia, hepatic injury, psychiatric issues), discontinue use and seek specialist care.
Drug interactions (examples)
- Concomitant use with anticoagulants (warfarin) may alter coagulation; monitoring required.
- May affect glycemic control — adjust antidiabetic therapy as needed with monitoring.
- Co‑administration with other hepatotoxic drugs increases liver risk (more relevant for oral methenolone acetate).
- Interactions with other endocrine therapies (e.g., corticosteroids, other androgenic agents) may modify effects and risks.
If discontinuing after prolonged use
- Expect gradual recovery of endogenous testosterone production; recovery time varies and can be prolonged (weeks to months). In some cases, endocrine consultation and interventions may be needed (e.g., for symptomatic hypogonadism or infertility).
5. Storage (How to store it)
- Store injectable methenolone (Primo 100 mg/mL) in its original container, tightly closed.
- Typical recommended temperature: store at controlled room temperature (generally 20–25°C / 68–77°F) — follow the product label for exact temperature range.
- Protect from light and excessive heat. Do not freeze.
- Keep out of reach of children and pets.
- For single‑use vials: do not reuse needles or syringes; follow local regulations and facility procedures for safe disposal of sharps.
- For multi‑dose vials: follow the manufacturer’s guidance on preservatives and discard time after puncture; use aseptic technique to avoid contamination.
- Disposal: unused medication and sharps should be disposed of according to local regulations (take‑back programs, pharmacy returns, or approved household sharps containers), not flushed down drains or thrown in household trash unless local guidance permits.
Final notes
- Methenolone is a medically active androgenic/anabolic steroid with a distinct pharmacologic profile and potential clinical applications, but it carries important risks and regulatory restrictions. Any consideration of methenolone therapy should be managed by physicians experienced in endocrine or specialist care, with informed consent, appropriate indication, and structured monitoring. Non‑medical or unsupervised use is discouraged because of significant health and legal risks.
1. Description (Clinical summary)
Primo 100 mg/mL contains primobolan (generic name methenolone) as an esterified injectable formulation (commonly methenolone enanthate). Methenolone is a synthetic anabolic–androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Historically it has been used in some countries for catabolic states, chronic wasting, and to support recovery from illness (e.g., severe weight loss, wasting associated with chronic disease) and occasionally for osteoporosis. It is not a first‑line agent for most of these conditions, and availability and regulatory approval vary by country. In many jurisdictions methenolone is a controlled substance and should be used only under medical supervision.
Clinical properties summarized:
- Predominantly anabolic with relatively low androgenic activity compared with testosterone.
- Low propensity to aromatize to estrogen.
- Available as oral acetate (shorter acting) and injectable enanthate (longer acting). “Primo 100 mg/mL” implies an injectable preparation at 100 mg of methenolone per milliliter.
Always consult a licensed clinician before use.
2. How does primobolan work? (Mechanism of action)
- Methenolone acts primarily as an agonist at the androgen receptor (AR). Activation of the AR in muscle and other tissues increases transcription of genes that promote protein synthesis, nitrogen retention, and growth of lean body mass.
- As a DHT derivative, methenolone is resistant to aromatization (conversion to estrogen). This characteristic reduces estrogen‑mediated side effects such as gynecomastia and fluid retention.
- It exerts relatively weak androgenic effects compared with testosterone, which may translate to a lower incidence of virilization and androgenic side effects at comparable anabolic doses—but risk remains, especially at higher doses or in women.
- Like other exogenous androgens, methenolone suppresses the hypothalamic–pituitary–gonadal (HPG) axis, reducing endogenous luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) secretion and thereby decreasing natural testosterone production.
- Pharmacokinetics depend on the ester: enanthate is a long‑acting ester released slowly from the injection site, producing sustained levels over days to weeks; the acetate form is shorter acting and often dosed daily.
3. Dosage (Medical and varying usage guidelines)
Important: Dose recommendations below are approximate and drawn from historical/clinical reports. Methenolone use should only occur under medical prescription and supervision. Non‑medical or high‑dose use for performance enhancement is associated with increased adverse effects and legal/ethical issues.
Medical (therapeutic) dosing — general historical ranges:
- Methenolone enanthate (injectable): commonly reported therapeutic doses have ranged from 50 to 100 mg administered intramuscularly at intervals of about 7–14 days. Exact dose and interval depend on indication, patient factors (age, sex, comorbidities), and clinician judgement.
- Methenolone acetate (oral): historically used in lower daily doses; clinicians used lower doses than other oral AAS because of different potency and tolerability.
Women:
- If used medically (rare), markedly lower doses are typically chosen (for example, substantially lower than male doses) because of the risk of virilization. Any use in women requires careful risk–benefit assessment and close monitoring.
Duration of therapy:
- Acute/short courses (weeks to a few months) were typically used for catabolic states under monitoring. Prolonged use increases risks (cardiovascular, endocrine, hepatic) and should be avoided unless specifically indicated and monitored.
Non‑medical/athletic use (for awareness and harm‑reduction):
- Reports in the bodybuilding community describe much higher doses (e.g., 200–400 mg/week or more) than therapeutic regimens. Such dosing significantly increases adverse effects (cardiovascular, endocrine, psychiatric, hepatologic). The medical community does not recommend such use.
- Women using methenolone for performance frequently develop virilizing effects even at lower doses; therefore use is discouraged.
Dosing and administration notes:
- Injectable methenolone enanthate is administered intramuscularly into a large muscle (e.g., gluteus). Aseptic technique and appropriate needle size for IM injection should be used.
- Timing: enanthate ester provides sustained release — clinicians often space injections weekly or every 10–14 days depending on clinical response and blood levels.
- Missed doses: if under medical therapy and a dose is missed, contact the prescriber for individualized advice rather than self‑adjusting intervals.
Monitoring:
- Baseline and periodic monitoring should include liver function tests (LFTs), fasting lipid profile, complete blood count (CBC) including hematocrit, blood pressure, and, in men, serum testosterone and PSA (if indicated by age/history). Women should be monitored closely for signs of virilization.
- Treatment duration should be minimized to the shortest effective period, with clear criteria for discontinuation.
4. Side effects (Common and rare adverse effects)
Adverse effects depend on dose, duration, formulation, patient sex, and individual susceptibility. Below are commonly reported and less common/serious effects.
Common / likely adverse effects:
- Suppression of endogenous testosterone production (HPG axis suppression) — can lead to testicular atrophy, decreased sperm production, low libido, and fatigue.
- Changes in lipid profile — decreased HDL (“good” cholesterol), increased LDL (“bad” cholesterol), increasing cardiovascular risk with prolonged use.
- Acne and oily skin.
- Increased aggression, mood changes, irritability, or psychiatric symptoms in some users.
- Injection site reactions (pain, swelling) for IM preparations.
Risks particularly relevant to women:
- Virilization (deepening voice, hirsutism, clitoral enlargement, menstrual disturbances). Some virilizing changes may be irreversible.
Less common but serious / rare adverse effects:
- Erythrocytosis (increased hematocrit) — raises risk of thrombotic events.
- Liver toxicity: methenolone enanthate (injectable) has less hepatotoxicity than 17α‑alkylated oral AAS, but liver monitoring is still recommended; oral acetate form is more hepatically taxing than injectable forms.
- Worsening of preexisting prostate disease (in men), and potential stimulation of prostate tissue.
- Adverse lipid changes contributing to increased long‑term cardiovascular morbidity (atherosclerosis, myocardial infarction, stroke).
- Unfavorable glucose tolerance changes — can affect glycemic control in people with diabetes.
- Allergic hypersensitivity reactions (rare).
Contraindications:
- Pregnancy and breastfeeding (risk of fetal virilization and developmental harm) — absolutely contraindicated.
- Known prostate or breast cancer (or suspect androgen‑sensitive malignancy).
- Serious cardiac, hepatic, or renal disease (relative/absolute contraindications depend on clinician).
- Known hypersensitivity to methenolone or formulation excipients.
Drug interactions (selected):
- Oral anticoagulants (e.g., warfarin) — AAS can potentiate or unpredictably alter anticoagulant effects; monitoring INR is necessary if co‑administered.
- Insulin and oral hypoglycemic agents — androgen therapy can alter glucose metabolism, requiring dose adjustments and monitoring.
- Corticosteroids — combined use can increase fluid retention and edema.
- Other hepatotoxic medications — additive risk for liver injury (especially with oral AAS).
Emergency signs (seek urgent medical care):
- Chest pain, sudden shortness of breath, signs of stroke (face weakness, slurred speech), marked calf pain (possible thrombosis), jaundice, severe abdominal pain, or severe psychiatric disturbances (severe aggression, suicidal ideation).
5. Storage (How to store it)
- Store at controlled room temperature, typically 20–25°C (68–77°F), unless the manufacturer label specifies otherwise.
- Protect from direct sunlight and excessive heat. Do not freeze.
- Keep in the original container with label intact to avoid dosing errors.
- Keep out of reach of children and pets.
- For injectable vials: use aseptic technique when drawing doses. Single‑dose vials should not be reused. If multi‑dose vials are used, follow manufacturer guidance for preservative and expiration after first puncture; discard if contamination is suspected or if beyond recommended in‑use period.
- Dispose of needles/syringes and any unused product following local regulations for medical/sharp waste — do not dispose in household trash.
- Do not use if the solution is discolored, cloudy (unless it is supposed to be an oil-in-water formulation as per label), or contains particulate matter; return to pharmacist or prescriber.
Final important notes
- Methenolone is a prescription medication in many places and may be a controlled substance. Use only as prescribed and under regular medical review.
- Non‑medical use for physique or performance enhancement carries legal, ethical, and significant health risks. If a person has used AAS and experiences concerning symptoms or wishes to stop, they should see a healthcare professional experienced in managing AAS withdrawal and endocrine recovery.
- If you have further questions about dosing for a specific medical indication, monitoring frequency, or potential interactions with other medications you take, consult your prescribing clinician or pharmacist.
